Compare ALLT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | CCCC |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.6M | 185.1M |
| IPO Year | 2006 | 2020 |
| Metric | ALLT | CCCC |
|---|---|---|
| Price | $6.38 | $2.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $12.25 | $12.20 |
| AVG Volume (30 Days) | 695.5K | ★ 2.8M |
| Earning Date | 02-25-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $15.84 | N/A |
| Revenue Next Year | $12.08 | N/A |
| P/E Ratio | $469.21 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $4.37 | $1.09 |
| 52 Week High | $11.92 | $3.82 |
| Indicator | ALLT | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 29.38 | 51.50 |
| Support Level | $6.20 | $2.35 |
| Resistance Level | $8.10 | $2.71 |
| Average True Range (ATR) | 0.28 | 0.26 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 7.32 | 13.07 |
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.